Literature DB >> 33727587

Altered left atrial 4D flow characteristics in patients with paroxysmal atrial fibrillation in the absence of apparent remodeling.

Marco J W Götte1, Robin Nijveldt2,3, Ahmet Demirkiran1, Raquel P Amier1, Mark B M Hofman4, Rob J van der Geest5, Lourens F H J Robbers1, Luuk H G A Hopman1, Mark J Mulder1, Peter van de Ven6, Cornelis P Allaart1, Albert C van Rossum1.   

Abstract

The pathophysiology behind thrombus formation in paroxysmal atrial fibrillation (AF) patients is very complex. This can be due to left atrial (LA) flow changes, remodeling, or both. We investigated differences for cardiovascular magnetic resonance (CMR)-derived LA 4D flow and remodeling characteristics between paroxysmal AF patients and patients without cardiac disease. In this proof-of-concept study, the 4D flow data were acquired in 10 patients with paroxysmal AF (age = 61 ± 8 years) and 5 age/gender matched controls (age = 56 ± 1 years) during sinus rhythm. The following LA and LA appendage flow parameters were obtained: flow velocity (mean, peak), stasis defined as the relative volume with velocities < 10 cm/s, and kinetic energy (KE). Furthermore, LA global strain values were derived from b-SSFP cine images using dedicated CMR feature-tracking software. Even in sinus rhythm, LA mean and peak flow velocities over the entire cardiac cycle were significantly lower in paroxysmal AF patients compared to controls [(13.1 ± 2.4 cm/s vs. 16.7 ± 2.1 cm/s, p = 0.01) and (19.3 ± 4.7 cm/s vs. 26.8 ± 5.5 cm/s, p = 0.02), respectively]. Moreover, paroxysmal AF patients expressed more stasis of blood than controls both in the LA (43.2 ± 10.8% vs. 27.8 ± 7.9%, p = 0.01) and in the LA appendage (73.3 ± 5.7% vs. 52.8 ± 16.2%, p = 0.04). With respect to energetics, paroxysmal AF patients demonstrated lower mean and peak KE values (indexed to maximum LA volume) than controls. No significant differences were observed for LA volume, function, and strain parameters between the groups. Global LA flow dynamics in paroxysmal AF patients appear to be impaired including mean/peak flow velocity, stasis fraction, and KE, partly independent of LA remodeling. This pathophysiological flow pattern may be of clinical value to explain the increased incidence of thromboembolic events in paroxysmal AF patients, in the absence of actual AF or LA remodeling.

Entities:  

Mesh:

Year:  2021        PMID: 33727587      PMCID: PMC7966746          DOI: 10.1038/s41598-021-85176-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  24 in total

1.  Determination of kinetic energy of the heart in man.

Authors:  O PREC; L N KATZ
Journal:  Am J Physiol       Date:  1949-12

2.  Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry.

Authors:  Melissa Leung; Philippe J van Rosendael; Rachid Abou; Nina Ajmone Marsan; Dominic Y Leung; Victoria Delgado; Jeroen J Bax
Journal:  Eur Heart J       Date:  2018-04-21       Impact factor: 29.983

Review 3.  Comprehensive 4D velocity mapping of the heart and great vessels by cardiovascular magnetic resonance.

Authors:  Michael Markl; Philip J Kilner; Tino Ebbers
Journal:  J Cardiovasc Magn Reson       Date:  2011-01-14       Impact factor: 5.364

Review 4.  Left atrial strain: A useful index in atrial fibrillation.

Authors:  Matteo Cameli; Giulia Elena Mandoli; Ferdinando Loiacono; Stefania Sparla; Elisabetta Iardino; Sergio Mondillo
Journal:  Int J Cardiol       Date:  2016-06-28       Impact factor: 4.164

5.  Three-dimensional left atrial blood flow characteristics in patients with atrial fibrillation assessed by 4D flow CMR.

Authors:  Daniel C Lee; Michael Markl; Jason Ng; Maria Carr; Brandon Benefield; James C Carr; Jeffrey J Goldberger
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-11-20       Impact factor: 6.875

6.  Left Atrial and Left Atrial Appendage 4D Blood Flow Dynamics in Atrial Fibrillation.

Authors:  Michael Markl; Daniel C Lee; Nicholas Furiasse; Maria Carr; Charles Foucar; Jason Ng; James Carr; Jeffrey J Goldberger
Journal:  Circ Cardiovasc Imaging       Date:  2016-09       Impact factor: 7.792

7.  Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.

Authors:  Stefan H Hohnloser; Dimitri Pajitnev; Janice Pogue; Jeff S Healey; Marc A Pfeffer; Salim Yusuf; Stuart J Connolly
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

8.  Quantification of left atrial strain and strain rate using Cardiovascular Magnetic Resonance myocardial feature tracking: a feasibility study.

Authors:  Johannes Tammo Kowallick; Shelby Kutty; Frank Edelmann; Amedeo Chiribiri; Adriana Villa; Michael Steinmetz; Jan Martin Sohns; Wieland Staab; Nuno Bettencourt; Christina Unterberg-Buchwald; Gerd Hasenfuß; Joachim Lotz; Andreas Schuster
Journal:  J Cardiovasc Magn Reson       Date:  2014-08-12       Impact factor: 5.364

9.  Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Authors:  Yasuhiro Hamatani; Hisashi Ogawa; Kensuke Takabayashi; Yugo Yamashita; Daisuke Takagi; Masahiro Esato; Yeong-Hwa Chun; Hikari Tsuji; Hiromichi Wada; Koji Hasegawa; Mitsuru Abe; Gregory Y H Lip; Masaharu Akao
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

10.  Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database.

Authors:  Hendrika A van den Ham; Olaf H Klungel; Daniel E Singer; Hubert G M Leufkens; Tjeerd P van Staa
Journal:  J Am Coll Cardiol       Date:  2015-10-27       Impact factor: 24.094

View more
  1 in total

1.  Left atrial evaluation by cardiovascular magnetic resonance: sensitive and unique biomarkers.

Authors:  Dana C Peters; Jérôme Lamy; Albert J Sinusas; Lauren A Baldassarre
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-12-18       Impact factor: 6.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.